title: [Topical timolol in the treatment of periocular superficial infantile hemangiomas: a prospective study].
abstract: OBJECTIVE
  To investigate the efficacy and side effect of topical beta-blocker (Timolol Maleate) in the treatment of periocular hemangioma in a prospective study.
  
  
  METHODS
  432 outpatients with infantile hemangioma visited our special clinic service in Shanghai Ninth People's Hospital from July 2010 to December 2011. Among them, 12 superficial periocular lesions were selected in the study. Timolol was used topically on the lesion in every 12 hours. Two independent special doctors evaluated the results according to the pictures before and after four-week application of timolol.
  
  
  RESULTS
  Were categorized into four levels: continuous growth (the lesion continues to grow), stable (no visible change), moderate (0-50% of regression) , perfect (more than 50% of improvement). Result of the 12 outpatients, 4 showed perfect result, 2 moderate, 4 stable and 2 continuous growth. No side effect was observed.
  
  
  CONCLUSIONS
  Topical timolol is effective and safe in the treatment of superficial periocular infantile hemangioma. It could be considered as the first line treatment of proliferative superficial hemangioma.
authors.affiliation: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
authors.forename: Xiao-xiao
authors.initials: XX
authors.lastname: Ye
authors.forename: Yun-bo
authors.initials: YB
authors.lastname: Jin
authors.forename: Xiao-xi
authors.initials: XX
authors.lastname: Lin
authors.forename: Gang
authors.initials: G
authors.lastname: Ma
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Chen
authors.forename: Ya-jing
authors.initials: YJ
authors.lastname: Qiu
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.forename: Xiao-jie
authors.initials: XJ
authors.lastname: Hu
mesh_terms: D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002681:China; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology; D018324:Hemangioma, Capillary / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007223:Infant; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013999:Timolol / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D013999:Timolol